KR102474830B1 - 중이염의 치료 - Google Patents

중이염의 치료 Download PDF

Info

Publication number
KR102474830B1
KR102474830B1 KR1020187036629A KR20187036629A KR102474830B1 KR 102474830 B1 KR102474830 B1 KR 102474830B1 KR 1020187036629 A KR1020187036629 A KR 1020187036629A KR 20187036629 A KR20187036629 A KR 20187036629A KR 102474830 B1 KR102474830 B1 KR 102474830B1
Authority
KR
South Korea
Prior art keywords
composition
subject
treatment
ebselen
tinnitus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187036629A
Other languages
English (en)
Korean (ko)
Other versions
KR20190043499A (ko
Inventor
조나단 킬
Original Assignee
사운드 파마슈티칼스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사운드 파마슈티칼스 인코퍼레이티드 filed Critical 사운드 파마슈티칼스 인코퍼레이티드
Publication of KR20190043499A publication Critical patent/KR20190043499A/ko
Application granted granted Critical
Publication of KR102474830B1 publication Critical patent/KR102474830B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020187036629A 2016-05-18 2017-05-18 중이염의 치료 Active KR102474830B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338443P 2016-05-18 2016-05-18
US62/338,443 2016-05-18
PCT/US2017/033379 WO2017201318A1 (en) 2016-05-18 2017-05-18 Treatment of meniere's disease

Publications (2)

Publication Number Publication Date
KR20190043499A KR20190043499A (ko) 2019-04-26
KR102474830B1 true KR102474830B1 (ko) 2022-12-06

Family

ID=60326098

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187036629A Active KR102474830B1 (ko) 2016-05-18 2017-05-18 중이염의 치료

Country Status (20)

Country Link
US (2) US12427138B2 (cg-RX-API-DMAC7.html)
EP (2) EP3458045B1 (cg-RX-API-DMAC7.html)
JP (1) JP7100866B2 (cg-RX-API-DMAC7.html)
KR (1) KR102474830B1 (cg-RX-API-DMAC7.html)
CN (2) CN122516370A (cg-RX-API-DMAC7.html)
AU (1) AU2017267732B2 (cg-RX-API-DMAC7.html)
CA (1) CA3026007A1 (cg-RX-API-DMAC7.html)
CY (1) CY1127309T1 (cg-RX-API-DMAC7.html)
DK (1) DK3458045T3 (cg-RX-API-DMAC7.html)
ES (1) ES2990157T3 (cg-RX-API-DMAC7.html)
FI (1) FI3458045T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241559T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069280T2 (cg-RX-API-DMAC7.html)
LT (1) LT3458045T (cg-RX-API-DMAC7.html)
PL (1) PL3458045T3 (cg-RX-API-DMAC7.html)
PT (1) PT3458045T (cg-RX-API-DMAC7.html)
RS (1) RS66167B1 (cg-RX-API-DMAC7.html)
SI (1) SI3458045T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400469T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017201318A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102981462B1 (ko) 2020-02-24 2026-06-23 상하이테크 유니버시티 N-치환 피리딜벤즈이소셀레나졸론 화합물의 용도
CN113288895B (zh) * 2021-06-21 2026-06-23 北华大学 一种用于治疗梅尼埃症的药物及其应用
JP2025504263A (ja) * 2021-12-23 2025-02-10 ユニバーシティ オブ ロチェスター 内耳への薬剤の送達のためのcsf輸送経路
WO2023240092A1 (en) 2022-06-06 2023-12-14 Sound Pharmaceuticals Inc. Ebselen containing oral dosage forms
EP4536192A1 (en) 2022-06-06 2025-04-16 Sound Pharmaceuticals Incorporated Amorphous dosage form containing ebselen
WO2026073143A1 (en) * 2024-09-27 2026-04-02 Sound Pharmaceuticals Inc. Cochlear implant eluting ebselen for treating hearing loss

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220145A1 (en) * 2002-01-04 2004-11-04 Sound Pharmaceuticals Incorporated Methods for treating hearing loss

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827093A1 (de) 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
JPH02202818A (ja) 1988-12-09 1990-08-10 Allergan Inc 白内障の治療における2―置換―チアゾリジン―4―カルボン酸類の用途
US20070105782A1 (en) 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
JP5236641B2 (ja) * 2006-07-25 2013-07-17 ハフ イヤ インスティテュート 急性音響外傷の治療方法
EP2310038A4 (en) * 2008-05-15 2012-03-14 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCE OF IMPROVENCE WITH COMPOUNDS WITH ERYTHROPOETIN EFFECT
CN106344495A (zh) 2008-12-22 2017-01-25 奥德纳米有限公司 用于治疗耳部病症的控制释放耳感觉细胞调节剂组合物
WO2012106654A1 (en) * 2011-02-04 2012-08-09 Hough Ear Institute Methods for treating brain injury
EP2736890A4 (en) 2011-07-28 2015-07-15 Promentis Pharm Inc Cysteine PRODRUGS
CN102526734A (zh) 2012-01-12 2012-07-04 王玉丰 治疗年龄相关性听力损失的药物组合物及其应用
US20150374779A1 (en) 2014-06-26 2015-12-31 Auris Medical Ag Pharmacologic treatments of meniére's disease
AU2015317877A1 (en) 2014-09-15 2017-05-04 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
US10750005B2 (en) 2018-09-27 2020-08-18 International Business Machines Corporation Selective email narration system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220145A1 (en) * 2002-01-04 2004-11-04 Sound Pharmaceuticals Incorporated Methods for treating hearing loss

Also Published As

Publication number Publication date
CN122516370A (zh) 2026-08-07
CY1127309T1 (el) 2026-02-25
CN109475518A (zh) 2019-03-15
PT3458045T (pt) 2024-10-28
KR20190043499A (ko) 2019-04-26
DK3458045T3 (da) 2024-11-04
EP4461360A2 (en) 2024-11-13
RS66167B1 (sr) 2024-12-31
EP4461360A3 (en) 2025-01-22
LT3458045T (lt) 2024-12-10
HUE069280T2 (hu) 2025-02-28
EP3458045A4 (en) 2020-09-16
JP7100866B2 (ja) 2022-07-14
SMT202400469T1 (it) 2025-01-14
ES2990157T3 (es) 2024-11-29
FI3458045T3 (fi) 2024-10-24
CN109475518B (zh) 2026-05-08
EP3458045B1 (en) 2024-08-21
PL3458045T3 (pl) 2025-01-07
JP2019516727A (ja) 2019-06-20
US20200261417A1 (en) 2020-08-20
US12427138B2 (en) 2025-09-30
SI3458045T1 (sl) 2025-03-31
EP3458045A1 (en) 2019-03-27
AU2017267732A1 (en) 2018-12-20
US20260166010A1 (en) 2026-06-18
CA3026007A1 (en) 2017-11-23
HRP20241559T1 (hr) 2025-02-14
WO2017201318A1 (en) 2017-11-23
AU2017267732B2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
EP3458045B1 (en) Ebselen for use in the treatment of meniere's disease
US10835546B2 (en) App specific BACE inhibitors (ASBIs) and uses thereof
CN103974619B (zh) 治疗法布里病的给药方案
JP2023169413A (ja) 精神病性障害を治療するための方法および組成物
US20240277641A1 (en) Methods for treating nervous system disorders with antipurinergic agents
EP3664786B1 (en) Method for treating schnitzler's syndrome
WO1998008504A1 (en) Remedies for allergic dermatitis
US20050209339A1 (en) Methods for the treatment of sinusitis
WO2025228863A1 (en) Dose regimen for a 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivative
CN104352496A (zh) 7-叔丁氧亚氨基甲基喜树碱用于治疗子宫肿瘤的用途
Shipman HIPAA: an impediment to research

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4